This site is intended for healthcare professionals

Specialty hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 23rd Apr 2021

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Learning Zones

Major depressive disorder and treatment-resistant depression

Learning Zone Homepage

Major depressive disorder and treatment-resistant depression

135 mins

MS: learnings from the pandemic and innovations in patient care

Learning Zone Homepage

MS: learnings from the pandemic and innovations in patient care

145 mins

Anticoagulation Therapy for Stroke Prevention

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

500 mins

COMT inhibition in Parkinson’s Disease

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

70 mins

One Neuroscience and Pain Learning Zone

Learning Zone Homepage

One Neuroscience and Pain Learning Zone

830 mins

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Depression

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Eli Lilly releases donanemab data from the Phase II TRAILBLAZER-ALZ study, that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline.

Today at the Alzheimer's Association International Conference (AAIC 2021), Eli Lilly and Company presented two new exploratory analyses of data from the Phase II TRAILBLAZER-ALZ study.

1 mins

FDA approves fexinidazole as the first all-oral treatment for sleeping sickness.

The FDA has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients 6 years of age and older and weighing at least 20 kg.

1 min

Kyowa Kirin provides update on application for istradefylline in Europe for the treatment of Parkinson’s.

Kyowa Kirin Co., Ltd. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination.

1 min

See all news

Related Drugs

Galantamine 4mg/ml Oral Solution

Galantamine 4mg/ml Oral Solution

17 mins

Fycompa film-coated tablets (Northern Ireland)

Fycompa film-coated tablets (Northern Ireland)

38 mins

Fycompa 0.5mg/ml oral suspension (Northern Ireland)

Fycompa 0.5mg/ml oral suspension (Northern Ireland)

37 mins

Atomoxetine 40mg Capsules

Atomoxetine 40mg Capsules

29 mins

Atomoxetine 18 mg hard capsules

Atomoxetine 18 mg hard capsules

29 mins

Atomoxetine 10mg Capsules

Atomoxetine 10mg Capsules

29 mins

Amantadine Syrup 50mg

Amantadine Syrup 50mg

13 mins

Amantadine hydrochloride 100mg capsules

Amantadine hydrochloride 100mg capsules

10 mins

Alzest 13.3 mg/24 h Transdermal Patch

Alzest 13.3 mg/24 h Transdermal Patch

26 mins

Altridexamol 1000 mg Effervescent Tablets

Altridexamol 1000 mg Effervescent Tablets

8 mins

Pizotifen 1.5mg Tablets.

Pizotifen 1.5mg Tablets.

5 mins

Pizotifen 0.5mg Tablets

Pizotifen 0.5mg Tablets

5 mins

Levetiracetam Mylan 1000 mg film-coated tablets

Levetiracetam Mylan 1000 mg film-coated tablets

26 mins

Ajovy (fremanezumab) 225 mg Pre-filled Pen for Injection

Ajovy (fremanezumab) 225 mg Pre-filled Pen for Injection

18 mins

Zebinix 800 mg tablets

Zebinix 800 mg tablets

28 mins

Related Journals

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

1 mins

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

1 mins

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

1 mins

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

1 mins

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

1 mins

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

1 mins

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

1 mins

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

1 mins

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

1 mins

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

1 mins

Related Guidelines

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

These recommendations were designed to ensure safety for patients with major depressive disorder (MDD) and to aid monitoring and management of adverse effects during treatment with approved antidepressant medications. The recommendations aim to inform prescribers about both the risks associated with these treatments and approaches for mitigating such risks.

1 mins

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use.

1 min

Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Background: Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.

1 min

See all guidelines

Related Clinical Trials

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

2 mins

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

1 mins

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

1 mins

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

1 mins

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

1 mins

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

1 mins

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

1 mins

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

2 mins

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Related Events

European Paediatric Neurology Society (EPNS) Congress 2022

1 mins

International Conference on Psychology (ICP) 2022

International Conference on Psychology (ICP) 2022

1 mins

Novartis sponsored satellite symposium at the 7th Congress of the European Academy of Neurology

Novartis sponsored satellite symposium at the 7th Congress of the European Academy of Neurology

1 mins

39th International Congress of Psychology

39th International Congress of Psychology

1 mins

34th ECNP Congress

34th ECNP Congress

1 mins

1 mins

7th Congress of the European Academy of Neurology - Virtual 2021

7th Congress of the European Academy of Neurology - Virtual 2021

1 mins

EAACI Hybrid Congress 2021

EAACI Hybrid Congress 2021

1 mins

Your peers are looking at...

Opdivo indication for hepatocellular carcinoma (liver cancer) withdrawn from FDA.- BMS

Opdivo indication for hepatocellular carcinoma (liver cancer) withdrawn from FDA.- BMS

1 mins

European Commission approves Opdivo as adjuvant treatment for esophageal or gastroesophageal junction cancer patients with residual pathologic disease following chemoradiotherapy.- BMS

European Commission approves Opdivo as adjuvant treatment for esophageal or gastroesophageal junction cancer patients with residual pathologic disease following chemoradiotherapy.- BMS

1 mins

Arvinas Inc., and Pfizer Inc., announce a global collaboration to develop and commercialize PROTAC Protein degrader ARV 471.

Arvinas Inc., and Pfizer Inc., announce a global collaboration to develop and commercialize PROTAC Protein degrader ARV 471.

1 mins

Merck Inc., announced positive overall survival results from the pivotal phase III KEYNOTE-355 trial evaluating Keytruda, + chemotherapy for the treatment of patients with metastatic triple-negative breast cancer .

Merck Inc., announced positive overall survival results from the pivotal phase III KEYNOTE-355 trial evaluating Keytruda, + chemotherapy for the treatment of patients with metastatic triple-negative breast cancer .

1 mins

Complete Response Letter from FDA for NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.- Ardelyx.

Complete Response Letter from FDA for NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.- Ardelyx.

1 mins

Eli Lilly releases donanemab data from the Phase II TRAILBLAZER-ALZ study, that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline.

Eli Lilly releases donanemab data from the Phase II TRAILBLAZER-ALZ study, that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline.

1 mins

Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review

Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review

1 mins

Chronic Kidney Disease Diagnosis and Management: A Review

Chronic Kidney Disease Diagnosis and Management: A Review

1 mins

Personalized medicine in chronic kidney disease by detection of monogenic mutations

Personalized medicine in chronic kidney disease by detection of monogenic mutations

1 mins

Integrated multi-omics approaches to improve classification of chronic kidney disease

Integrated multi-omics approaches to improve classification of chronic kidney disease

1 mins